Ignite Creation Date:
2024-05-06 @ 7:20 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05976906
Status:
RECRUITING
Last Update Posted:
2023-08-04
First Post:
2023-05-10
Brief Title:
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
A Study to Evaluate the Safety Tolerability Preliminary Efficacy Pharmacodynamics and Immunogenicity of Universal CNK-UT Cells in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single arm open-label multi-center phase I study to evaluate the safety tolerability preliminary efficacy pharmacodynamics and immunogenicity of universal chimeric natural killer receptor modified T-cells CNK-UT targeting NKG2D-Ligands and NCR2-Ligands with or without lymphodepletion in advanced solid tumors
Detailed Description:
This is a single arm open-label multi-center phase I dose escalationindications expansion study to assess the safety and tolerability of CNK-UT cells therapy and to obtain the preliminary efficacy pharmacodynamics and immunogenicity result in participants who have been diagnosed with advanced solid tumors and failed to standard systemic treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None